PURE Bioscience (PURE) Announces Earnings Results

PURE Bioscience (OTCMKTS:PURE) posted its quarterly earnings results on Wednesday. The company reported ($0.03) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.02) by ($0.01), Bloomberg Earnings reports. The company had revenue of $0.41 million during the quarter, compared to the consensus estimate of $1.25 million. PURE Bioscience had a negative net margin of 388.83% and a negative return on equity of 210.88%.

Shares of PURE Bioscience (PURE) traded down $0.05 during midday trading on Thursday, reaching $0.69. The company’s stock had a trading volume of 59,414 shares, compared to its average volume of 44,294. The firm has a market cap of $50.95, a PE ratio of -6.74 and a beta of -1.55. PURE Bioscience has a 52-week low of $0.69 and a 52-week high of $1.36.

In other PURE Bioscience news, CEO Henry R. Lambert sold 41,500 shares of PURE Bioscience stock in a transaction on Friday, January 12th. The stock was sold at an average price of $0.93, for a total value of $38,595.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 10.56% of the stock is owned by insiders.

Separately, ValuEngine upgraded PURE Bioscience from a “sell” rating to a “hold” rating in a research note on Wednesday, November 29th.

WARNING: This piece was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/03/15/pure-bioscience-pure-announces-earnings-results.html.

PURE Bioscience Company Profile

PURE Bioscience, Inc is focused on developing and commercializing antimicrobial products that provide solutions to the health and environmental challenges of pathogen and hygienic control. The Company’s technology platform is based on stabilized ionic silver and its products contain silver dihydrogen citrate (SDC).

Earnings History for PURE Bioscience (OTCMKTS:PURE)

Receive News & Ratings for PURE Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PURE Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply